SILO Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	14 087.00
Gjennomsnittsvolum	206 796
Markedsverdi	5.26M
EPS	$0 ( 2024-03-25 )
Neste inntjeningsdato	( $0 ) 2024-06-24
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.570
ATR14	$0.0290 (1.57%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Weisblum Eric	Buy	400	Common Stock
2024-04-04	Weisblum Eric	Buy	600	Common Stock
2024-04-01	Weisblum Eric	Buy	1 100	Common Stock
2024-03-28	Weisblum Eric	Buy	3 408	Common Stock
2023-12-20	Weisblum Eric	Buy	200	Common Stock

INSIDER POWER
100.00
Last 55 transactions
Buy: 22 165 052 \| Sell: 3 696 660

Silo Pharma, Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Silo Pharma, Inc. Økonomi

Annual	2023
Omsetning:	$72 102.00
Bruttogevinst:	$-805 361 (-1 116.97 %)
EPS:	$-1.200

FY	2023
Omsetning:	$72 102.00
Bruttogevinst:	$-805 361 (-1 116.97 %)
EPS:	$-1.200

FY	2022
Omsetning:	$72 102.00
Bruttogevinst:	$66 264.00 (91.90 %)
EPS:	$-1.710

FY	2021
Omsetning:	$71 264.00
Bruttogevinst:	$66 260.00 (92.98 %)
EPS:	$2.00

Financial Reports:

No articles found.

Silo Pharma, Inc.

Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company focuses on merging traditional therapeutics with psychedelic research for patients with depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. It has a scientific research agreement with the University of Maryland, The Regents of the University of California, and Columbia University. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.